RxDoctor Payments DataLook up a doctor →

Jeffrey Stewart, MD

Family Medicine · Carrollton, TXNPI 1538145198

Payments from drug & device makers

$5,734,417in general payments, 2019–2025

Across 1,127 payments — averaging $5088.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$4.2M
  • Incyte Corporation$370K
  • Romark Laboratories, LC$344K
  • Sanofi US Services Inc.$216K
  • Alnylam Pharmaceuticals Inc.$156K
  • AbbVie$116K
  • plus $336K from 48 others
$390in research payments, 2019–2025

Across 1 payment — averaging $390.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$390

What the payments were for

  • Travel & lodging$90814%
  • Food & beverage$5,50286%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,734,417 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$108,009
Medicare patients
248
Services billed
1,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$32,573
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,912
Breo ElliptaFluticasone/Vilanterol12$4,906
Levothyroxine Sodium170$1,622
PaxlovidNirmatrelvir/Ritonavir14$1,429
Potassium Chloride28$1,259
Armour ThyroidThyroid,pork13$996
Bupropion XlBupropion Hcl33$940
Atorvastatin Calcium95$745
Ezetimibe20$744
Tamsulosin Hcl36$629
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$617
Omeprazole49$553
Metformin Hcl79$538
Zolpidem Tartrate63$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$270$32,57334 claims
GSKAnoro Ellipta, Breo Ellipta$13,889$10,81825 claims
PfizerPaxlovid$109,525$1,42914 claims
AbbVieArmour Thyroid$115,861$99613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →